| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 48,698 | 56,125 | ||
| Prepaid expenses and other current assets | 2,694 | 2,545 | ||
| Research and development incentives receivables | 1,015 | 2,751 | ||
| Total current assets | 52,407 | 61,421 | ||
| Property and equipment, at cost | 1,221 | - | ||
| Less accumulated depreciation | 1,047 | - | ||
| Property and equipment, net | 174 | 218 | ||
| Operating lease right of use assets, net | 378 | 522 | ||
| Intangible assets, net | 643 | 470 | ||
| Total assets | 53,602 | 62,631 | ||
| Accounts payable | 879 | 1,138 | ||
| Accrued expenses | 4,118 | 5,041 | ||
| Convertible loan notes - current | 0 | 0 | ||
| Operating lease liabilities - current | 397 | 601 | ||
| Other current liabilities | 622 | 777 | ||
| Total current liabilities | 6,016 | 7,557 | ||
| Warrant liabilities - non-current | 336 | 545 | ||
| Operating lease liabilities- non-current | 0 | 0 | ||
| Other non-current liabilities | 652 | 352 | ||
| Total liabilities | 7,004 | 8,454 | ||
| Ordinary shares, par value 0.003 per share 795,484,404 shares issued at september 30, 2025 (december 31, 2024 775,728,034) | 3,134 | 3,132 | ||
| Additional paid-in capital | 548,041 | 546,331 | ||
| Accumulated deficit | -493,667 | -486,643 | ||
| Accumulated other comprehensive loss | -10,910 | -8,643 | ||
| Total shareholders' equity | 46,598 | 54,177 | ||
| Total liabilities and shareholders' equity | 53,602 | 62,631 | ||
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)